Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age

Pediatric Infectious Disease Journal

Volumn 29, Issue 4, 2010, Pages 374-376

  Stensballe, Lone G ^a   Fullarton, John R ^b   Carbonell Estrany, Xavier ^c   Simões, Eric A F ^d  

^a STATENS SERUM INSTITUT   (Denmark)

^b Strategen Limited   (United Kingdom)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIRTH WEIGHT; BREAST FEEDING; CHILD HOSPITALIZATION; DIAGNOSTIC ACCURACY; EUROPE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MODEL; POPULATION RESEARCH; PREDICTION; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SIBLING; VALIDATION STUDY; VIRUS INFECTION;

EID: 77950271977     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c810da     Document Type: Article

References (9)

1. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23: 806-814.
2. Connor EM; The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants [see comments]. Pediatrics. 1998;102:531-537.
3. Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12:iii, ix-x, 1-86.
4. Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-820.
5. Simoes EA, Carbonell-Estrany X, Fullarton JR, et al. A predictive model for respiratory syncytial virus (RSV) hospitalization of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9:78.
6. Olsen J, Melbye M, Olsen SF, et al. The Danish National Birth Cohort\ its background, structure and aim. Scand J Public Health. 2001;29:300-307.
7. Stensballe LG, Kristensen K, Simoes EA, et al. Atopic disposition, wheezing, and subsequent respiratory syncytial virus hospitalization in Danish children younger than 18 months: a nested case-control study. Pediatrics. 2006;118:e1360-e1368.
8. Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23:S193-S201.
9. Paes B, Steele S, Janes M, et al. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin. 2009;25:1585-1591.